Rosetta Genomics Announces Study Validating miRview mets2 Published in The Oncologist
Rosetta Genomics Ltd. (NASDAQ: ROSG) today announced that data from studies of miRview® mets² in patients with Cancer of Unknown and Uncertain Primary were published online in The Oncologist in an article titled, "A second generation microRNA-based assay for diagnosing tumor tissue origin: An improved microRNA-based mets assay."
The study demonstrated the ability of the miRview® mets² assay to identify 42 tumor types with high accuracy and to maintain the same performance in samples from patients clinically diagnosed with CUP, showing an 88% concordance with the clinico-pathological evaluation of the patients. The article can be accessed online at www.ncbi.nlm.nih.gov/pubmed/22618571 and is expected to be published in the print edition of The Oncologist.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.